Remedi Establishes ‘RemediX’ and Builds India Plant

Remedi has established its Indian subsidiary ‘RemediX’ and will complete a compact X-ray plant in Greater Noida by September. The facility, with a monthly capacity of up to 300 units, will integrate production, training, and after-sales service to support local operations.

Etnews | 2026.04.22

Selected as ‘K-Export Star 500,’ Accelerating Global Market Expansion

Remedi has been selected for the “2026 K-Export Star 500,” recognizing its export competitiveness. Leveraging the program’s funding, the company plans to strengthen field-based medical marketing in high tuberculosis-burden countries across Asia and accelerate the global expansion of its ultra-portable X-ray solutions.

Rapportian | 2026.04.22

Remedi Selected as a ‘2026 Global Sustainable Brands 100’

Remedi has been selected for the “2026 Global Sustainable Leaders, Companies, and Brands 100” by the UN SDGs Association, and recognized as one of the Top 50 Global Sustainable Brands recommended to consumers. This recognition is based on 43 criteria, including ESG, innovation, and sustainability, highlighting Remedi’s contribution to sustainable healthcare.

Seqye Ilbo | 2026.04.13

Featured on G1 ‘Top Class,’ Irena Highlights Portable X-ray Innovation

On G1’s “Top Class,” Professor Irena, founder of Remedi, was featured for advancing medical accessibility through ultra-portable X-ray technology, highlighting its use beyond hospitals and its global potential.

G1 | 2026.04.06

Remedi–POSCO International Sign MOU for Tuberculosis Screening Project in Indonesia

Remedi has signed an MOU with POSCO International to collaborate on a tuberculosis screening project in Indonesia and expand into global markets. The partnership will begin in Indonesia and extend to other high-burden countries, strengthening mobile healthcare through combined global networks and technology.

Kangwon Ilbo | 2026.04.05

Remedi Expands Global Business Collaboration with POSCO International

Remedi has signed a cooperation agreement with POSCO International to advance into the global public healthcare market, starting with a tuberculosis screening project in Indonesia. The partnership combines Remedi’s ultra-compact X-ray technology with POSCO International’s global network to expand across emerging and developed markets.

Moneytoday | 2026.04.03

India TB Elimination Project: Supply of 1,534 REMEX-KA6 Units

Remedi has been selected as the supplier of its portable X-ray system, REMEX-KA6, for the Indian government’s National Tuberculosis Elimination Program (NTEP) equipment tender. The company will supply a total of 1,534 units and provide three years of after-sales service. The devices are expected to be used for mobile tuberculosis screening.

Digitalchosun | 2026.02.26

Remedi Pursues IPO on Profit Turnaround

Remedi has achieved a return to profitability through revenue growth and improved margins, and is now pursuing its third IPO attempt. Leveraging its portable X-ray technology, the company is expanding its global presence and demonstrating both technical strength and growth potential through achievements such as participation in NASA projects.

Bloter | 2026.02.18

“Xcam6” Selected for Space Mission After NASA Evaluation

Remedi’s ultra-compact X-ray “Xcam6” has been selected for a space mission following NASA evaluation. It will be deployed on a SpaceX crewed spacecraft in 2026 for astronaut diagnostics and spacecraft inspection, with potential use on the International Space Station.

Digitalchosun | 2026.02.09

Remedi, Selected for NASA Space Mission

Remedi’s ultra-compact X-ray “Xcam6” has been selected as a NASA flight test device. It will be used aboard a SpaceX crewed spacecraft for astronaut imaging and non-destructivetesting, with potential expansion to ISS and deep space missions.

Gangwonilbo | 2026.02.09

Xcam6 Deployed on NASA Spacecraft

Remedi’s ultra-compact portable X-ray system, Xcam6, has been selected as a flight test device for a NASA mission. Chosen after approximately 18 months of evaluation among more than 200 global candidates, it will be used for astronaut diagnosis and non-destructive inspection of spacecraft and equipment.

Dongascience | 2026.02.09

Remedi’s Portable X-ray Selected for NASA Mission

Remedi’s portable X-ray system has been adopted for a NASA mission, demonstrating the expansion of Korean medical technology into the space industry. With its ultra-lightweight design and high-resolution imaging, the device is expected to be used for non-destructive inspection of space equipment, with potential for broader application in future exploration missions.

MBC | 2026.02.09

Remedi Accelerates Growth with IPO Rechallenge

Remedi is pursuing a KOSDAQ listing again, backed by its proven global competitiveness in portable X-ray technology. The company supplies products to 43 countries, expanding overseas demand while achieving revenue growth and profitability. Through this IPO, Remedi aims to accelerate R&D and global expansion.

Money today | 2026.02.08

Medical AI Integration… Remedi Advances Platform Strategy

Remedi is accelerating its platform strategy through medical AI integration. In collaboration with JLK, it strengthens competitiveness with a lung diagnostic solution package while advancing toward an AI-integrated business and IPO.

The bell | 2026.02.02

Remedi Reapplies for KOSDAQ Listing

Remedi has filed for a preliminary review with the Korea Exchange for a KOSDAQ technology-special listing. This marks its third attempt at going public, having secured the required technology evaluation ratings. The company has also strengthened revenue stability and predictability by establishing a repeat-order structure centered on public healthcare demand.

The bell | 2026.01.30

AI Healthcare Partnership with Hippocrates Labs

Remedi has signed an MOU with Hippocrates Labs to introduce an AI-based clinical summarization system for next-generation healthcare. By integrating AI into its EMR system, Remedi aims to reduce clinicians’ workload and improve data management efficiency, while leveraging blockchain-based security for use in underserved regions.

Dailymedi | 2025.12.19

Selected for NASA Project, Demonstrating Mini X-ray Technology

Remedi has been selected for a space medical technology project at NASA’s Glenn Research Center, demonstrating its global competitiveness. REMEX-KA6 is lightweight, low-dose, and enables on-site diagnostics, making it suitable for both space and underserved regions. Remedi supplies its products to over 50 countries in collaboration with WHO and IAEA.

The JoongAng | 2025.09.29

KNTA Partners with Remedi for TB Screening

The Seoul Metropolitan Branch of the Korean National Tuberculosis Association has partnered with Remedi to improve TB and lung disease screening for vulnerable populations. Remedi’s X-ray systems will be deployed across screening sites, supporting data-based analysis and enhanced diagnostic accuracy.

MDTODAY | 2025.07.22

REMEDI delivers medical volunteer service in Cambodia with ultralight X-ray

REMEDI brought its 2.4kg portable X-ray (KA6) to Cambodia, enabling quick diagnosis in underserved areas. Powered by battery and low-dose radiation, KA6 supported both medical care and staff training—showcasing the impact of tech donation.

Edaily | 2025.06.23

Remedi Designated as a Global Leading Company of Korea, 2025

On June 27, REMEDI was selected for the 2025 Global Small Giant 1,000+ Project. As a leading exporter of portable X-ray devices, we aim to grow through advanced product development and global certifications.

Kangwon Ilbo | 2025.06.23

REMEDI Expands Access to Healthcare in the Philippines with Portable X-ray Systems

Remedi has brought portable X-ray devices to remote Philippine regions, improving diagnostic access. Partnering with local organizations, Remedi is launching mobile clinics and plans to add AI diagnostics and training for sustainable healthcare.

Stop TB Partnership | 2025.05.23

Remedi Showcases Innovative Radiation Technologies at ICARST 2025

Remedi’s portable X-ray device, Remex-KA6, drew significant attention from IAEA and global experts at ICARST 2025. Remedi’s lightweight X-ray delivers quality imaging with low radiation and is gaining global traction.

Edaily | 2025.04.15

REMEX Xcam6 Approved in Japan, Speeds Up Market Penetration

Remedi’s lightweight X-ray device, Remex Xcam6, received Japanese approval in just six months and is now on sale, offering high-quality imaging at one-third the radiation dose of traditional equipment.

Edaily | 2025.03.20

REMEDI sells Products to NASA, Anticipates Use in Space Exploration Equipment

Remedi, founded by Professor Irena of Ewha Womans University, has sold its self-developed portable X-ray device to NASA. Recognized for its low radiation, lightweight, and mobility, the device is expected to be used in space and specialized settings.

KwNews | 2024.10.02